<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4542">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238640</url>
  </required_header>
  <id_info>
    <org_study_id>NICTDP1072</org_study_id>
    <secondary_id>2008-002788-15</secondary_id>
    <nct_id>NCT01238640</nct_id>
  </id_info>
  <brief_title>Bioequivalence Between Two New Oral Nicotine Replacement Therapy Products and Nicorette® Microtab</brief_title>
  <official_title>Bioequivalence Between Two New Oral Nicotine Replacement Therapy Products and Nicorette® Microtab. A Study in Healthy Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence between two new oral nicotine
      replacement therapy products and Nicorette® microtab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial has a single-dose, randomized, crossover design and includes 84 subjects. The
      investigational products will be given as single doses at separate treatment visits. Periods
      without Nicotine Replacement Therapy (NRT), lasting for at least 36 hours, will separate
      treatment visits. At each treatment visit, blood for pharmacokinetic analyses will be
      sampled immediately before, and at 5, 10, 15, 20, 30, and 45 minutes, as well as at 1, 1.25,
      1.5, 2, 3, 4, 6, 8, and 10 hours after start of product administration. The time until
      complete tablet dissolution will be recorded. Subjects will also be monitored to capture any
      adverse events that may occur. Treatment labels will be concealed from subjects and study
      personnel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>During 10 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, which is the maximum observed plasma concentration after a dose is administered, measured in nanograms/milliliter (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC(0-t)]</measure>
    <time_frame>During 10 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bioavailability within the Set Period [AUC(0-t)] is the area under the plasma concentration verses time curve from start of drug administration until the time of the last measurable plasma concentration, calculated as hour * nanograms (ng) per milliliter (mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-∞)</measure>
    <time_frame>10 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC (0-∞) is the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time. It is obtained from calculating AUC (0-t) plus AUC (t-∞).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Product Dissolution Time</measure>
    <time_frame>During 10 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Dissolution Time is the time from administration until the investigational products were completely dissolved.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>Code STD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An experimental 2 mg nicotine product coded &quot;STD&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Code STE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An experimental 2 mg nicotine product coded &quot;STE&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicorette Microtab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A comparative 2 mg marketed nicotine product called Nicorette Microtab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Code STD</intervention_name>
    <description>2 mg Single-dose of experimental nicotine product coded &quot;STD&quot;</description>
    <arm_group_label>Code STD</arm_group_label>
    <other_name>Not marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Code STE</intervention_name>
    <description>2 mg Single-dose of experimental nicotine product coded &quot;STE&quot;</description>
    <arm_group_label>Code STE</arm_group_label>
    <other_name>Not marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicorette Microtab</intervention_name>
    <description>A comparative 2 mg Single-dose of marketed tablet</description>
    <arm_group_label>Nicorette Microtab</arm_group_label>
    <other_name>Nicorette® Microtab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects, smoking at least 10 cigarettes daily during at least one year
             preceding inclusion and BMI between 17.5 and 30.0 kg/m2.

          -  Female participants of child-bearing potential are required to use a medically
             acceptable means of birth control.

          -  A personally signed and dated informed consent document, indicating that the subject
             has been informed of all pertinent aspects of the study.

        Exclusion Criteria:

          -  Pregnancy, lactation or intended pregnancy.

          -  Treatment with an investigational product or donation or loss of blood within 3 month
             preceding the first dose of study medication.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Kruse, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McNeil AB Clinical Pharmacology R&amp;D</name>
      <address>
        <city>Lund</city>
        <zip>SE-222 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 6, 2012</lastchanged_date>
  <firstreceived_date>November 9, 2010</firstreceived_date>
  <firstreceived_results_date>March 11, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Nicotine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="84"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32.2" spread="9.32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="49"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Sweden</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="84"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <description>Cmax, which is the maximum observed plasma concentration after a dose is administered, measured in nanograms/milliliter (ng/mL)</description>
        <time_frame>During 10 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>STD 2 mg</title>
            <description>An experimental 2 mg nicotine product coded &quot;STD&quot;</description>
          </group>
          <group group_id="O2">
            <title>STE 2 mg</title>
            <description>An experimental 2 mg nicotine product coded &quot;STE&quot;</description>
          </group>
          <group group_id="O3">
            <title>Nicorette Microtab 2 mg</title>
            <description>A comparative 2 mg marketed nicotine product called Nicorette Microtab</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="81"/>
                  <measurement group_id="O2" value="82"/>
                  <measurement group_id="O3" value="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Observed Plasma Concentration (Cmax)</title>
            <description>Cmax, which is the maximum observed plasma concentration after a dose is administered, measured in nanograms/milliliter (ng/mL)</description>
            <units>ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.90" spread="1.35"/>
                  <measurement group_id="O2" value="4.00" spread="1.37"/>
                  <measurement group_id="O3" value="4.08" spread="1.48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve [AUC(0-t)]</title>
        <description>Bioavailability within the Set Period [AUC(0-t)] is the area under the plasma concentration verses time curve from start of drug administration until the time of the last measurable plasma concentration, calculated as hour * nanograms (ng) per milliliter (mL).</description>
        <time_frame>During 10 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>STD 2 mg</title>
            <description>An experimental 2 mg nicotine product coded &quot;STD&quot;</description>
          </group>
          <group group_id="O2">
            <title>STE 2 mg</title>
            <description>An experimental 2 mg nicotine product coded &quot;STE&quot;</description>
          </group>
          <group group_id="O3">
            <title>Nicorette Microtab 2 mg</title>
            <description>A comparative 2 mg marketed nicotine product called Nicorette Microtab</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="82"/>
                  <measurement group_id="O3" value="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve [AUC(0-t)]</title>
            <description>Bioavailability within the Set Period [AUC(0-t)] is the area under the plasma concentration verses time curve from start of drug administration until the time of the last measurable plasma concentration, calculated as hour * nanograms (ng) per milliliter (mL).</description>
            <units>hr*ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12.69" spread="5.46"/>
                  <measurement group_id="O2" value="12.56" spread="5.36"/>
                  <measurement group_id="O3" value="13.01" spread="5.80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-∞)</title>
        <description>AUC (0-∞) is the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time. It is obtained from calculating AUC (0-t) plus AUC (t-∞).</description>
        <time_frame>10 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>STD 2 mg</title>
            <description>An experimental 2 mg nicotine product coded &quot;STD&quot;</description>
          </group>
          <group group_id="O2">
            <title>STE 2 mg</title>
            <description>An experimental 2 mg nicotine product coded &quot;STE&quot;</description>
          </group>
          <group group_id="O3">
            <title>Nicorette Microtab 2 mg</title>
            <description>A comparative 2 mg marketed nicotine product called Nicorette Microtab</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="82"/>
                  <measurement group_id="O3" value="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC(0-∞)</title>
            <description>AUC (0-∞) is the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time. It is obtained from calculating AUC (0-t) plus AUC (t-∞).</description>
            <units>hr*ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15.74" spread="6.33"/>
                  <measurement group_id="O2" value="15.09" spread="6.62"/>
                  <measurement group_id="O3" value="15.57" spread="7.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Dissolution Time</title>
        <description>Product Dissolution Time is the time from administration until the investigational products were completely dissolved.</description>
        <time_frame>During 10 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>STD 2 mg</title>
            <description>An experimental 2 mg nicotine product coded &quot;STD&quot;</description>
          </group>
          <group group_id="O2">
            <title>STE 2 mg</title>
            <description>An experimental 2 mg nicotine product coded &quot;STE&quot;</description>
          </group>
          <group group_id="O3">
            <title>Nicorette Microtab 2 mg</title>
            <description>A comparative 2 mg marketed nicotine product called Nicorette Microtab</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                  <measurement group_id="O2" value="83"/>
                  <measurement group_id="O3" value="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Product Dissolution Time</title>
            <description>Product Dissolution Time is the time from administration until the investigational products were completely dissolved.</description>
            <units>Minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23.3" spread="8.90"/>
                  <measurement group_id="O2" value="23.8" spread="10.22"/>
                  <measurement group_id="O3" value="25.0" spread="6.33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>STD 2 mg</title>
          <description>An experimental 2 mg nicotine product coded &quot;STD&quot;</description>
        </group>
        <group group_id="E2">
          <title>STE 2 mg</title>
          <description>An experimental 2 mg nicotine product coded &quot;STE&quot;</description>
        </group>
        <group group_id="E3">
          <title>Nicorette Microtab 2 mg</title>
          <description>A comparative 2 mg marketed nicotine product called Nicorette Microtab</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joyce Hauze, RPS Sr. Specialist, Clinical Research Operations</name_or_title>
      <organization>Johnson &amp; Johnson Consumer and Personal Products Worldwide</organization>
      <phone>928-277-0715</phone>
      <email>jhaue@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
